Hong Kong Pharma Digital Technology (HKPD) Financials

$1.58 +0.06 (+3.59%)

Closing price 03:56 PM Eastern

Extended Trading

$1.58 0.00 (-0.25%)

As of 05:08 PM Eastern

Annual Income Statements for Hong Kong Pharma Digital Technology

This table shows Hong Kong Pharma Digital Technology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2023	2024	2025	2026
Period end date	3/31/2023	3/31/2024	3/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	1.00	2.66	-0.03	-2.29
Consolidated Net Income / (Loss)	1.00	1.33	-0.03	-1.14
Net Income / (Loss) Continuing Operations	1.00	1.33	-0.03	-1.14
Total Pre-Tax Income	1.02	1.53	0.04	-1.13
Total Operating Income	0.95	-1.95	0.13	-2.39
Total Gross Profit	2.74	3.56	2.42	1.39
Total Revenue	13	17	20	13
Operating Revenue	13	17	20	13
Total Cost of Revenue	9.82	13	18	12
Operating Cost of Revenue	9.82	13	18	12
Total Operating Expenses	1.76	1.89	2.22	2.40
Selling, General & Admin Expense	1.76	1.89	2.22	2.40
Total Other Income / (Expense), net	0.07	-0.08	-0.10	-0.13
Interest Expense	-	0.08	-	0.13
Interest & Investment Income	-	0.00	-	0.00
Other Income / (Expense), net	0.07	-0.06	-0.10	0.01
Income Tax Expense	0.02	0.20	0.06	0.01
Basic Earnings per Share	-	$0.18	-	($0.07)
Weighted Average Basic Shares Outstanding	6.84M	7.37M	10.21M	16.35M
Diluted Earnings per Share	-	$0.18	-	($0.07)
Weighted Average Diluted Shares Outstanding	6.84M	7.37M	10.21M	16.35M
Weighted Average Basic & Diluted Shares Outstanding	13.69M	-	20.41M	16.35M

No quarterly income statements for Hong Kong Pharma Digital Technology are available.

This table details how cash moves in and out of Hong Kong Pharma Digital Technology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2023	2024	2025	2026
Period end date	3/31/2023	3/31/2024	3/31/2025	3/31/2026
Net Change in Cash & Equivalents	2.57	5.69	0.75	-3.42
Net Cash From Operating Activities	2.64	4.48	0.22	-2.43
Net Cash From Continuing Operating Activities	2.64	4.48	0.22	-2.43
Net Income / (Loss) Continuing Operations	1.00	1.33	-0.03	-1.14
Consolidated Net Income / (Loss)	1.00	1.33	-0.03	-1.14
Depreciation Expense	0.07	0.06	0.08	0.09
Non-Cash Adjustments To Reconcile Net Income	-0.46	0.78	-0.93	0.44
Changes in Operating Assets and Liabilities, net	2.03	2.31	1.10	-1.82
Net Cash From Investing Activities	0.00	0.03	0.00	0.00
Net Cash From Continuing Investing Activities	0.00	0.03	0.00	0.00
Sale of Property, Plant & Equipment	0.00	0.03	0.00	0.00
Net Cash From Financing Activities	-0.07	1.18	0.53	-0.99
Net Cash From Continuing Financing Activities	-0.07	1.18	0.53	-0.99
Repayment of Debt	-0.07	-0.20	-0.24	-0.99
Issuance of Debt	0.00	1.37	0.77	0.00
Cash Interest Paid	0.06	0.08	0.10	0.09

No quarterly cash flow statements for Hong Kong Pharma Digital Technology are available.

This table presents Hong Kong Pharma Digital Technology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2025	2026
Period end date	3/31/2024	3/31/2025	3/31/2026
Total Assets	8.67	9.42	13
Total Current Assets	6.54	6.47	12
Cash & Equivalents	0.62	0.75	0.22
Restricted Cash	0.01	0.00	0.00
Accounts Receivable	4.98	5.16	12
Inventories, net	0.93	0.56	0.36
Plant, Property, & Equipment, net	0.10	0.11	0.06
Total Noncurrent Assets	2.02	2.84	0.45
Intangible Assets	0.03	0.10	0.08
Other Noncurrent Operating Assets	1.99	2.74	0.38
Total Liabilities & Shareholders' Equity	8.67	9.42	13
Total Liabilities	4.41	4.43	3.26
Total Current Liabilities	3.18	2.92	3.20
Short-Term Debt	0.22	0.37	0.88
Accounts Payable	1.42	1.82	0.87
Current Deferred & Payable Income Tax Liabilities	0.22	0.11	0.02
Other Current Liabilities	1.33	0.62	1.43
Total Noncurrent Liabilities	1.24	1.51	0.07
Long-Term Debt	1.12	1.50	0.00
Capital Lease Obligations	0.12	0.01	0.07
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	4.25	4.99	9.58
Total Preferred & Common Equity	4.25	4.99	9.58
Total Common Equity	4.25	4.99	9.58
Common Stock	3.03	3.47	8.97
Retained Earnings	1.53	1.50	0.37
Accumulated Other Comprehensive Income / (Loss)	-0.00	0.01	-0.01
Other Equity Adjustments	-0.30	0.00	0.25

No quarterly balance sheets for Hong Kong Pharma Digital Technology are available.

This table displays calculated financial ratios and metrics derived from Hong Kong Pharma Digital Technology's official financial filings.

Metric	2023	2024	2025	2026
Period end date	3/31/2023	3/31/2024	3/31/2025	3/31/2026
DEI Shares Outstanding	0.00	0.00	0.00	16,349,986.00
DEI Adjusted Shares Outstanding	0.00	0.00	0.00	16,349,986.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	0.00	0.00	-0.14
Growth Metrics	-	-	-	-
Revenue Growth	0.00%	33.26%	21.32%	-33.65%
EBITDA Growth	0.00%	-278.60%	105.72%	-2,148.18%
EBIT Growth	0.00%	-297.83%	101.79%	-6,685.07%
NOPAT Growth	0.00%	-283.76%	94.18%	-1,585.20%
Net Income Growth	0.00%	33.21%	-102.03%	-4,098.56%
EPS Growth	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	0.00%	69.47%	-95.08%	-1,203.60%
Free Cash Flow Firm Growth	0.00%	0.00%	83.15%	-412.11%
Invested Capital Growth	0.00%	0.00%	20.55%	68.31%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-
Gross Margin	21.87%	21.32%	11.93%	10.32%
EBITDA Margin	8.74%	-11.72%	0.55%	-17.06%
Operating Margin	7.57%	-11.71%	0.65%	-17.77%
EBIT Margin	8.15%	-12.10%	0.18%	-17.70%
Profit (Net Income) Margin	7.97%	7.97%	-0.13%	-8.46%
Tax Burden Percent	97.79%	87.14%	-74.92%	100.68%
Interest Burden Percent	100.00%	-75.56%	100.00%	47.45%
Effective Tax Rate	2.21%	12.86%	174.92%	0.00%
Return on Invested Capital (ROIC)	0.00%	-67.07%	-1.77%	-20.34%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	668.11%	5.59%	37.33%
Return on Net Nonoperating Assets (RNNOA)	0.00%	129.59%	1.18%	4.75%
Return on Equity (ROE)	0.00%	62.52%	-0.59%	-15.59%
Cash Return on Invested Capital (CROIC)	0.00%	-267.07%	-20.41%	-71.26%
Operating Return on Assets (OROA)	0.00%	-23.30%	0.40%	-21.36%
Return on Assets (ROA)	0.00%	15.34%	-0.30%	-10.21%
Return on Common Equity (ROCE)	0.00%	62.52%	-0.59%	-15.59%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	0.93	-1.70	-0.10	-1.67
NOPAT Margin	7.40%	-10.21%	-0.49%	-12.44%
Net Nonoperating Expense Percent (NNEP)	0.00%	-735.18%	-7.36%	-57.67%
Return On Investment Capital (ROIC_SIMPLE)	-	-29.85%	-1.44%	-15.87%
Cost of Revenue to Revenue	78.39%	78.68%	88.40%	89.68%
SG&A Expenses to Revenue	14.04%	11.32%	10.94%	17.83%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	14.04%	11.32%	10.94%	17.83%
Earnings before Interest and Taxes (EBIT)	1.02	-2.02	0.04	-2.38
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1.09	-1.96	0.11	-2.29
Valuation Ratios	-	-	-	-
Price to Book Value (P/BV)	0.00	1.32	1.13	0.97
Price to Tangible Book Value (P/TBV)	0.00	1.33	1.15	0.98
Price to Revenue (P/Rev)	0.45	0.34	0.28	0.69
Price to Earnings (P/E)	5.62	2.11	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%
Earnings Yield	17.78%	47.36%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	1.27	1.10	0.97
Enterprise Value to Revenue (EV/Rev)	0.00	0.39	0.33	0.75
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	60.31	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	186.85	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	1.44	30.61	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-
Debt to Equity	0.00	0.34	0.38	0.10
Long-Term Debt to Equity	0.00	0.29	0.30	0.01
Financial Leverage	0.00	0.19	0.21	0.13
Leverage Ratio	0.00	2.04	1.96	1.53
Compound Leverage Factor	0.00	-1.54	1.96	0.72
Debt to Total Capital	0.00%	25.45%	27.39%	8.96%
Short-Term Debt to Total Capital	0.00%	3.77%	5.41%	8.34%
Long-Term Debt to Total Capital	0.00%	21.68%	21.98%	0.62%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	74.55%	72.62%	91.04%
Debt to EBITDA	0.00	-0.74	16.82	-0.41
Net Debt to EBITDA	0.00	-0.42	10.12	-0.31
Long-Term Debt to EBITDA	0.00	-0.63	13.50	-0.03
Debt to NOPAT	0.00	-0.85	-18.98	-0.56
Net Debt to NOPAT	0.00	-0.48	-11.43	-0.43
Long-Term Debt to NOPAT	0.00	-0.73	-15.23	-0.04
Altman Z-Score	0.00	2.63	3.60	3.04
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-
Current Ratio	0.00	2.06	2.22	3.86
Quick Ratio	0.00	1.76	2.03	3.75
Cash Flow Metrics	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-6.78	-1.14	-5.85
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	-81.94	0.00	-43.73
Operating Cash Flow to Interest Expense	0.00	54.14	0.00	-18.17
Operating Cash Flow Less CapEx to Interest Expense	0.00	54.54	0.00	-18.17
Efficiency Ratios	-	-	-	-
Asset Turnover	0.00	1.93	2.24	1.21
Accounts Receivable Turnover	0.00	3.35	3.99	1.59
Inventory Turnover	0.00	14.07	23.97	26.19
Fixed Asset Turnover	0.00	161.64	188.79	158.12
Accounts Payable Turnover	0.00	9.27	11.06	8.94
Days Sales Outstanding (DSO)	0.00	108.94	91.42	229.77
Days Inventory Outstanding (DIO)	0.00	25.95	15.23	13.94
Days Payable Outstanding (DPO)	0.00	39.37	33.02	40.84
Cash Conversion Cycle (CCC)	0.00	95.52	73.63	202.87
Capital & Investment Metrics	-	-	-	-
Invested Capital	0.00	5.08	6.12	10
Invested Capital Turnover	0.00	6.57	3.62	1.64
Increase / (Decrease) in Invested Capital	0.00	5.08	1.04	4.18
Enterprise Value (EV)	0.00	6.44	6.75	10
Market Capitalization	5.61	5.61	5.61	9.29
Book Value per Share	$0.00	$0.58	$0.49	$0.59
Tangible Book Value per Share	$0.00	$0.57	$0.48	$0.58
Total Capital	0.00	5.71	6.87	11
Total Debt	0.00	1.45	1.88	0.94
Total Long-Term Debt	0.00	1.24	1.51	0.07
Net Debt	0.00	0.83	1.13	0.72
Capital Expenditures (CapEx)	0.00	-0.03	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	2.95	3.18	9.79
Debt-free Net Working Capital (DFNWC)	0.00	3.58	3.92	10
Net Working Capital (NWC)	0.00	3.37	3.55	9.14
Net Nonoperating Expense (NNE)	-0.07	-3.03	-0.07	-0.53
Net Nonoperating Obligations (NNO)	0.00	0.83	1.13	0.72
Total Depreciation and Amortization (D&A)	0.07	0.06	0.08	0.09
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	17.70%	15.68%	72.90%
Debt-free Net Working Capital to Revenue	0.00%	21.45%	19.38%	74.56%
Net Working Capital to Revenue	0.00%	20.16%	17.55%	68.02%
Earnings Adjustments	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	($0.07)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	11M	16.35M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	($0.07)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	11M	16.35M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	20.41M	16.35M
Normalized Net Operating Profit after Tax (NOPAT)	0.93	-1.70	0.09	-1.67
Normalized NOPAT Margin	7.40%	-10.21%	0.46%	-12.44%
Pre Tax Income Margin	8.15%	9.14%	0.18%	-8.40%
Debt Service Ratios	-	-	-	-
EBIT to Interest Expense	0.00	-24.40	0.00	-17.77
NOPAT to Interest Expense	0.00	-20.58	0.00	-12.48
EBIT Less CapEx to Interest Expense	0.00	-24.00	0.00	-17.77
NOPAT Less CapEx to Interest Expense	0.00	-20.18	0.00	-12.48
Payout Ratios	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%

No quarterly metrics and ratios for Hong Kong Pharma Digital Technology are available.

Financials Breakdown Chart

Hong Kong Pharma Digital Technology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Hong Kong Pharma Digital Technology's financial year ends in March. Their financial year 2026 ended on March 31, 2026.

Hong Kong Pharma Digital Technology's net income appears to be on a downward trend, with a most recent value of -$1.14 million in 2026, compared with $998.20 thousand in 2023. The previous period was -$27.06 thousand in 2025. Find out what analysts predict for Hong Kong Pharma Digital Technology in the coming months.

Hong Kong Pharma Digital Technology's total operating income in 2026 was -$2.39 million, based on the following breakdown:

Total Gross Profit: $1.39 million
Total Operating Expenses: $2.40 million

Over the last 3 years, Hong Kong Pharma Digital Technology's total revenue changed from $12.52 million in 2023 to $13.43 million in 2026, a change of 7.3%.

Hong Kong Pharma Digital Technology had total debt of $943.18 thousand at the end of 2026, a 49.9% decrease from 2025, and none in 2023.

Over the last 3 years, Hong Kong Pharma Digital Technology's book value per share changed from 0.00 in 2023 to 0.59 in 2026, a change of 58.6%.

Related Companies

Financial statements for NASDAQ:HKPD last updated on 10/26/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hong Kong Pharma Digital Technology (HKPD) Financials

Financials Breakdown Chart

Hong Kong Pharma Digital Technology Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hong Kong Pharma Digital Technology (HKPD) Financials

Annual Income Statements for Hong Kong Pharma Digital Technology

Quarterly Income Statements for Hong Kong Pharma Digital Technology

Annual Cash Flow Statements for Hong Kong Pharma Digital Technology

Quarterly Cash Flow Statements for Hong Kong Pharma Digital Technology

Annual Balance Sheets for Hong Kong Pharma Digital Technology

Quarterly Balance Sheets for Hong Kong Pharma Digital Technology

Annual Metrics And Ratios for Hong Kong Pharma Digital Technology

Quarterly Metrics And Ratios for Hong Kong Pharma Digital Technology

Financials Breakdown Chart

Hong Kong Pharma Digital Technology Financials - Frequently Asked Questions

When does Hong Kong Pharma Digital Technology's fiscal year end?

How has Hong Kong Pharma Digital Technology's net income changed over the last 3 years?

What is Hong Kong Pharma Digital Technology's operating income?

How has Hong Kong Pharma Digital Technology's revenue changed over the last 3 years?

How much debt does Hong Kong Pharma Digital Technology have?

How has Hong Kong Pharma Digital Technology's book value per share changed over the last 3 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools